Send us a text

Discover a smarter way to manage and share market access resources with local affiliates

Are your global market access resources scattered, leading to inconsistencies and confusion among your affiliates? In this webinar we discussed how a centralised platform can streamline resource sharing, ensure access to nationally-relevant evidence, and put the resources your local affiliates need right at their fingertips. The webinar features a conversation with Tim Styche (Market Access & Health Outcomes Director, Smith+Nephew), who shares how his team has solved this challenge with our Global Value Platform.

Learn more at: https://petauri.com/insights/transforming-global-market-access-smarter-resource-management-with-local-affiliates-a-live-webinar/

To discuss your needs or arrange a full demo of the platform email evidence@petauri.com

Subscribe to our newsletter to hear more news, insights and events from Petauri Evidence

Send us a text

What do global market access teams need to know about the US market? What do US payers expect to hear from Pharma and Medtech companies? What kind of value messaging resonates in the US? How do you prepare for launch in a market as diverse as the US?

In this Global Whispers episode, Louise Maddison (Senior Consultant – Global Market Access, Petauri Evidence) interviews some of our colleagues from Petauri Advisors who are either former payers, or former industry market access leads in the US. Louise puts your questions to:

- Rory Davies – Vice President of Value and Access, Petauri Advisors, with extensive past experience in Chief Clinical roles at Cigna, Flipt and WellDyne
- Dan Vanderpoel – Executive Vice President, Strategic Payer Marketing; Head, Client Solutions, Petauri and former Manager, Trade Relations at Humana
- Shana Gunderson Hua – Vice President of Value and Access, Petauri Advisors and former Medical Affairs Executive Director at Genentech and former AVP of Pharmaceutical Strategy and Contracting at Cigna and Express Scripts (now Evernorth)

We explore what global market access teams need to know about market access and payer engagement in the US. We explore how and why value messaging, pricing, and launch strategies are developed differently for the US market, compared to other key launch markets, and what this means for global teams preparing for US launch or taking a US-developed proposition internationally.

Learn more at: https://petauri.com/insights/communicating-value-to-us-payers-insights-for-pharma-and-medtech/

This episode was first broadcast live as a webinar in March 2025.

Learn more about Petauri Evidence: https://petauri.com/petauri-evidence/

Learn more about Petauri Advisors: https://petauri.com/petauri-advisors/

Meet the ACE team: https://petauri.com/about-us/ace-team/

Subscribe to our newsletter to hear more news, insights and events from Petauri Evidence

Send us a text

Discover how health economics can support successful Medical Device launch, proposition development, and market access

This episode offers an insightful journey into the world of medical device market access. Specialists from our health economics and market access teams explore the hidden challenges faced by medical devices companies when taking new innovations to healthcare leaders, communicating value and demonstrating evidence, and offer tips on leveraging health economics for a successful launch.

Juliet Wallace (Senior Partnerships Coordinator) delves deep with our expert panel into the pivotal role of health economic evaluation in supporting market access for medical devices. Juliet puts audience questions to Hannah Palin (Director, Local Market Access), Calum Jones (Associate Director, Health Economics), and Evelyne Priestman (Consultant, Health Economics).

See full details at: https://mtechaccess.co.uk/launch-strategies-health-economic-modelling-medical-devices/

This episode was originally broadcast live as webinar in February 2025.

https://petauri.com/

Subscribe to our newsletter to hear more news, insights and events from Petauri Evidence

Send us a text

What clinical and economic evidence do US payers prefer to drive formulary decisions? How can you optimise your chances of preferential access in the US with the right evidence? How should evidence be generated, synthesised, and presented for the US market?

In this episode, Clare Foy (Director – Global Market Access, Mtech Access) interviews colleagues Nicole Lodowski (Managing Director, Petauri Evidence) and Bob Nordyke (Senior Advisor, Petauri Evidence) about US payer evidence challenges.

We explore the evolving evidence needs for US payers. Nicole and Bob share unique perspectives around their extensive experience of driving evidence strategies for US pharmaceutical and medical device launches. Additionally, Nicole and Bob share a ‘sneak peek’ of exclusive insights from a recent Petauri US payer insights survey conducted to better understand the evidence landscape from the US payers’ perspective.

They explore:

• The evolving payer evidence landscape in the US
• Preferences for clinical and economic evidence by US payers
• Key differences between the US and other global markets with regard to evidence, HEOR, and market access
• Opportunities and challenges when launching new medicines/medical devices/diagnostics in the US
• Innovative perspectives on evidence planning and strategy for the US market
• US payers’ perspectives, with exclusive insights from Petauri Evidence’s 2024 US payer survey

This episode was first broadcast as a live webinar in October 2024. Learn more at: https://mtechaccess.co.uk/navigating-us-payer-evidence-needs/

Explore more about launching in the US market: https://mtechaccess.co.uk/launching-healthcare-products-in-the-us/

Subscribe to our newsletter to hear more news, insights and events from Petauri Evidence

Send us a text

How can real-world evidence (RWE) support health technology assessment (HTA)? Can real-world data (RWD) supplement clinical data? How can RWE be used to solve common challenges with treatment comparison?

Here, Mtech Access are joined by experts from Arcturis and Delta Hat. Dan Howard (Associate Director – Health Economics, Mtech Access) shares some of the challenges that our clients face when developing HTA-ready health economic models with limited clinical trial data. Joseph O’Reilly (Principal Medical Statistician, Arcturis) introduces solutions to these challenges using RWD and RWE approaches. Nick Latimer (Analyst, Delta Hat; Professor of Health Economics, University of Sheffield; former NICE Appraisal Committee member) discusses how RWE is assessed by HTA committees. Samantha Gillard (Director – HTA, Mtech Access) facilitates the discussion and puts your questions to our experts

This episode was first broadcast as a live webinar in October 2024. To request a copy of the slides used or to learn more visit: https://mtechaccess.co.uk/rwe-approaches-economic-modelling-hta/

For support with real-world evidence analysis, health economic modelling of health technology assessment, email info@mtechaccess.co.uk or visit https://mtechaccess.co.uk/

Subscribe to our newsletter to hear more news, insights and events from Petauri Evidence

Send us a text

How is the NHS preparing for winter? Which challenges are the most pressing for NHS decision-makers? How can industry best engage and support NHS decision-makers in the next few months?

In August, Karen Cooper (Senior Consultant – NHS Insight & Interaction, Mtech Access) was joined by Jo Turl (Former Director of Commissioning, Devon ICS) to explore these challenges.

Jo and Karen discuss:

• How ICBs and Directors of Commissioning prepare for winter pressures
• The current key areas of focus at Place and ICB level
• Specific challenges and pressures facing the NHS now and in the run up to winter
• Immediate and long-term impact of (expected) new government policies
• How industry can best support the NHS as it plans for winter and beyond
• How your field teams can engage with NHS commissioners over the next few months

This episode was first broadcast as a live webinar in August 2024.
Learn more at https://mtechaccess.co.uk/nhs-winter-planning/

For support with your UK market access and NHS engagement strategy, visit: https://mtechaccess.co.uk/strategic-uk-market-access/ or email info@mtechaccess.co.uk

Subscribe to our newsletter to hear more news, insights and events from Petauri Evidence

Send us a text

Are you a global market access lead looking to understand the challenges faced by your UK affiliates? Or do you work at a national level with responsibility for bringing a new health technology to the NHS in England? In July 2024, Global Whispers and NHS Whispers came together, to bring you an overarching view of what it takes to access the NHS with a medtech or pharmaceutical innovation.

Guest speaker Dr Faris Al-Ramadani who shared his experience of introducing new technologies to the NHS from both sides of the fence: as a PCN Clinical Director and GP Partner, and as a HealthTech and Venture Capital Consultant.

The NHS in England is complex and ever changing. Recent years have seen the introduction of new structures, new decision-makers and new priorities. If you’ve fallen out of the loop of what’s happening with the NHS, this webinar is here to help.

After de-ciphering some of the new(er) NHS terminologies and structures, we discuss:

• The key steps for introducing a new health technology to the NHS
• Who to speak to, when and where
• What to include in your value proposition to appeal to NHS decision-makers
• How to best meet key stakeholders’ needs
• The challenges of bringing a new technology to the NHS in England
  
  

Learn more about this webinar at: https://mtechaccess.co.uk/de-mystifying-the-nhs/

Discover more about how we can support your UK launch strategy at: https://mtechaccess.co.uk/strategic-uk-market-access/

This webinar was first broadcast live as a webinar in July 2024

Subscribe to our newsletter to hear more news, insights and events from Petauri Evidence

Send us a text

What can we expect to see in primary care in the NHS given recent policy announcements and ongoing uncertainty? What does the new GP Contract tell us about the future of primary care? What are the biggest challenges facing primary care in 2024–25?

In this webinar, Karen Cooper (Senior Consultant – NHS Insight & Interaction, Mtech Access) spoke to a panel of NHS Associates about the current state and future of primary care and what this means for industry. Our panellists were:
- Jack Wagstaff (Place Leader, Surrey Heartlands Health and Care Partnership, Chief Officer for North West Surrey Health and Care Alliance)
- Zafran Azam (Head of Medicines Optimisation and Delivery, Derby City Place)
- Dr Neil Forster (GP and PCN Clinical Director, Northumberland Medical Alliance)

We explore:
- Where NHS primary care is heading and what this means for your strategy and business planning
- Prescribing and decision-making in primary care
- The implications of the GP Contract for PCNs, GPs, patients, and industry
- What this means for integration and the integrated care model
- Policy priorities in practice and what to expect in an election year
- How Pharma, Medtech, and Diagnostics companies can best engage with primary care leaders

Learn more at: https://mtechaccess.co.uk/nhs-primary-care-gp-contract/

Discover more about our UK market access services at: https://mtechaccess.co.uk/uk-nhs-insights/

Subscribe to our newsletter to hear more news, insights and events from Petauri Evidence